Connect Biopharma is trading 5.13% up now at $2.35 after continued investor positioning ahead of the expected August 12, 2026, second-quarter earnings report.
- The report is listed with estimated -$0.32 EPS; no new clinical or regulatory announcement was identified.
- The Nasdaq Composite is up 0.64%, potentially adding to risk appetite for speculative biotechnology shares.